Recent Articles and Announcements
Press Release, July 17, 2018 - Perry Baromedical and Kent Imaging Inc. announce Strategic Partnership in Hyperbarics
RIVIERA BEACH, Florida, July 17, 2018 (CSN) — Perry Baromedical and Kent Imaging Inc. today announced a Strategic Partnership where Perry will distribute Kent’s Near Infrared Imaging device (SnapshotNIR).
Press Release, June 27, 2018 - Kent Imaging Inc. and SerenaGroup announce Strategic Partnership in wound care
CALGARY, Alberta, Canada, June 27, 2018 (CSN) — Kent Imaging Inc. and SerenaGroup® today announced a Strategic Partnership to jointly improve tissue assessment in wounds with the use of Near Infrared Imaging technology using Kent's SnapshotNIR device
Press Release, May 30, 2018 - Kent Imaging, Inc. Announces CE Mark for New Multispectral Imaging Product, Kent’s SnapshotNIR
CALGARY, Alberta, Canada, May 30, 2018 (CSN) — Kent Imaging, a leading provider of near infrared imaging solutions, announced today that it has received CE Mark approval for the Kent multispectral Medical Imaging Device (SnapshotNIR). The Kent device is also listed as a Class II medical device with US FDA and Health Canada. This now allows Kent to expand its markets with distribution in Europe.
Press Release, March 20, 2018 - Kent Imaging Announces Strategic Partnership to Advance Tissue Assessment
CALGARY, March 20, 2018 /CNW/ - Kent Imaging Inc. announced today a strategic relationship with Allergan Canada to advance tissue assessment in Canada. This opportunity adds the Kent device to Allegan Canada's Medical Aesthetics division with another solution for breast augmentation surgery along with AlloDerm®, Natrelle®, Revolve®, and the Keller Funnel®.
Today's Wound Clinic, January 4, 2018 - Near Infrared Spectroscopy & Predicting the Likelihood of Future Wound Healing
The SnapshotNIR device is an example of the rapidly emerging digital imaging assessment tools available to wound care providers for the management of chronic wounds. By establishing the condition of the wound bed and surrounding tissues, clinicians can actually predict whether or not a vascular component is influencing wound closure. Using this device, one can predict, up to one week in advance, that necrosis or dehiscence of a flap is probable.
Podiatry Today, November 16, 2017 - Can Multispectral Imaging Aid in Wound Care and Limb Salvage?
I have been using a new multispectral infrared camera, the SnapshotNIR (Kent Imaging), for a few weeks now. My patients and I have been wowed by the images but I have been impressed more by the relevant clinical information I have available to me instantly while treating my wound care patients.
News Release, November 14, 2017 -Kent Imaging Welcomes Clinical Leader, Dr. Adam Landsman, DPM, PhD as Chief Medical Officer
Dr. Landsman's exceptional background as the Assistant Professor of Surgery at Harvard Medical School will further Kent's medical device applications.
News Release, November 7, 2017 - Kent Imaging's Breakthrough Medical Imaging Device Licensed with Health Canada
Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, announced today that their handheld SnapshotNIR is a licensed medical device with Health Canada. Kent's device is also cleared with the U.S. Food and Drug Administration (FDA) and the company is ISO13485 certified.
News Release, November 1, 2017 - Jeff Hydar Joins Kent Imaging as Vice President of Sales, USA
Jeff Hydar is an award winning strategic sales executive who has run successful teams throughout the United States. Hydar's experience guiding sales teams and his motivational leadership style will propel Kent's product sales in the wound and surgical care market.
BioWorld MedTech, October 31, 2017 - Kent Imaging Says its Device is the First Line of Defense in Wound and Tissue Analysis
Whether it’s a chronic wound, acute injury or following surgical intervention, we give physicians the first line of defense to determine if the tissue has a chance to survive and remain viable.
DOTmed Health Care Business, October 24, 2017 - FDA Gives Green Light to Kent Imaging’s Perfusion Imaging Device, SnapshotNIR
The portable, hand-held device can collect data in less than a second using a variety of health applications, to provide physicians with simplified diagnostic readings and insights for analysis on the best course of treatment before, during and after clinical and surgical care.
News Release, October 19, 2017 - Kent Imaging Revolutionizes Perfusion Imaging with Their FDA Cleared SnapshotNIR
Kent's device is the next step in perfusion imaging by directly showing tissue oxygenation. The SnapshotNIR provides insight into the availability of oxygenated blood in tissue, which enables accurate diagnosis, improved treatment planning and effective patient monitoring.
News Release, April 29, 2017 - Kent Imaging Receives ISO 13485 Certification
Kent Imaging announced today that it has passed the ISO 13485 requirements for a comprehensive quality management system for the design and manufacture of medical devices. This new certification marks another key milestone in Kent’s continuous improvement strategy. It demonstrates Kent’s commitment to quality and customer satisfaction. Achieving this level of certification allows Kent to pursue additional regulatory clearances for its medical imaging device including Health Canada clearance.
Announcement, December 1, 2016 - Kent Imaging Hires Chief Scientist to Lead Product Research
Kent Imaging announced today the hiring of Dr. Michael Sowa for the role of Chief Scientist. Dr. Sowa brings over 24 years of structured research from his role as Group Leader and Principal Research Officer at the National Research Council of Canada (NRC). During his time at the NRC his was instrumental in their development of ICG angiography which technology lead to the creation of Novadaq and then went on to lead the team that developed the next generation of imaging technology – NIR spectroscopy which formed the basis of Kent’s products. Dr. Sowa will continue to lead the development of medical imaging being developed by Kent Imaging while also be responsible for Kent’s IP strategy.
Announcement, July 2, 2016 - Kent Imaging Appoints Healthcare Veteran as CEO
Kent Imaging announced today the appointment of seasoned medical imaging executive Pierre Lemire to the role of Chief Executive Officer. Mr. Lemire brings more than 30 years of experience in successfully launching new products to market. Prior to joining Kent Imaging, he co-founded Calgary Scientific and as President, led the company in becoming a global leader in medical imaging. He was also previously Chief Technology Officer for Autodesk, a Silicon Valley company. Kent founder Don Chapman will continue in his role as Executive Chairman assisting Mr. Lemire in launching the company’s new handheld imaging device.
Announcement, January 2, 2015 - Co-Developed OCT Spectroscopy Device Moving to Clinical Testing
Kent Imaging announced today that an OCT spectroscopy device, co-developed with the National Research Council of Canada (NRC), is moving to clinical testing. The completed new technology is being transported to a Toronto hospital to begin the first stage of clinical testing.
Announcement, January 1, 2015 - Italian Research Group Initiate Study
An Italian research group has submitted a protocol which will use the Kent Camera in an upcoming study to examining the benefits of hyperbaric oxygen therapy in venous ulcers. The study will recruit approximately 80 patients with venous ulcers. The Kent Camera will be used to non-invasively detect levels of oxy-hemoglobin and deoxy-hemoglobin in the superficial tissue.
Announcement, November 1, 2014 - Peggy Dotson and Matthew Livingston have Joined Kent’s Advisory Committee
Kent Imaging announced today that Peggy Dotson and Matthew Livingston have joined Kent’s advisory committee. Ms. Dotson is a business executive with over 35 years of experience in the healthcare and medical device industry. Ms. Dotson brings expertise in reimbursement analysis and strategy to the advisory committee.
Mr. Livingston has spent the last 15 years specializing in wound care and hyperbaric medicine. He has managed large in and out patient wound care centres and hyperbaric programs and is experienced in clinical research. Mr. Livingston will provide strategic guidance for the development of technologies.